A Phase 3 interventional study of GSK1024805A and Prevenar in Infections, Streptococcal and Streptococcus Pneumoniae Vaccines, sponsored by GlaxoSmithKline. Completed at 6 sites in Poland. Open to participants aged 28 Months to 32 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-27.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing PHiD-CV vaccine in Streptococcal Infections — none open to participants now, none under way, none of them phase 3. PHiD-CV vaccine · Streptococcal Infections.
Among the 25 studies testing PHiD-CV vaccine in Streptococcal Infections, this one is the 7th largest by enrollment, is one of 4 that started in 2008, is one of 24 in phase 3, and was the 6th registered.
147 studies on the registry are indexed under Streptococcal Infections; 14 are open to participants now.
Browse Streptococcal Infections studies →None of the 25 studies testing PHiD-CV vaccine in Streptococcal Infections is open now. The open studies under Streptococcal Infections, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 10 Streptococcal Infections studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.
This study: 28 Months to 32 Months · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 4 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 524 is above the median of 270 across 106 interventional studies indexed under Streptococcal Infections.
Median enrollment 360 across the 25 interventional studies. Of the 25 that completed or were terminated, 25 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 25 have an industry lead sponsor. The 1 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
64 studies in Streptococcal Infections by GlaxoSmithKline: 1 open now, 1 under way, none of them phase 3. Of 61 finished, 44 (72%) have results posted.
Among the 64 studies in Streptococcal Infections by GlaxoSmithKline, this one is the 19th largest by enrollment of the 55 interventional ones that give a count, is one of 9 that started in 2008, is one of 38 in phase 3, and was the 20th registered.
GlaxoSmithKline’s Streptococcal Infections studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 25 studies testing PHiD-CV vaccine in Streptococcal Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 64 in Streptococcal Infections:
This tab as a report to print or save as PDF → With an account.
This protocol posting deals with objectives \& outcome measures of the extension phase up to 48-50 months post booster vaccination, to assess long-term antibody persistence in children at around 30, 42 and 66 months of age, who received previously 4 doses of pneumococcal conjugate vaccine. The objectives \& outcome measures of the primary phase are presented in a separate protocol posting (NCT number = 00307554). This Protocol posting has been updated in order to comply with the FDA AA (Sep 2007).
This study consists in a serological follow-up study to evaluate persistence 12, 24 and 48 months after the booster vaccination study (107046). No study vaccines will be administered within this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This group consisted of subjects primed with Synflorix vaccine in the 10PN-PD-DIT-001 (1105553) and 007 (107046) studies. In 105553 study, subjects had been primed with 3 doses of Synflorix vaccine at 2, 3 and 4 months of age co-administered with Infanrix related vaccines. In 107046 study, subjects had received a booster dose of Synflorix vaccine at 12-18 months of age co-administered with Infanrix hexa vaccine. In this study, in the Year 4 (111347 study), subjects received at Month 48 (4 years post Dose 1 in study 105553) one additional dose of Synflorix vaccine. In addition, subjects were also offered vaccination against hepatitis A (2 doses of Havrix) and/or against varicella (a single dose of Varilrix).
Biological: GSK1024805A · Biological: Infanrix hexa · Biological: Havrix · Biological: Varilrix
This group consisted of subjects vaccinated with Prevenar vaccine in the 10PN-PD-DIT-001 (105553) and 007 (107046) studies. In 105553 study, subjects had been primed with 3 doses of Prevenar vaccine at 2, 3 and 4 months of age co-administered with Infanrix related vaccines. In 107046 study, subjects had received a booster dose at 12-18 months of age of Prevenar vaccine co-administered with Infanrix hexa vaccine. In this study, in the Year 4 111347 study, subjects had received at Month 48 (4 years post Dose 1 in study 105553) one dose of Synflorix vaccine. In addition, subjects were also offered vaccination against hepatitis A (2 doses of Havrix and/or against varicella (a single dose of Varilrix).
Biological: Prevenar · Biological: Infanrix hexa · Biological: Havrix · Biological: Varilrix
This group consisted of subjects vaccinated with Prevenar and Synflorix vaccines in the 10PN-PD-DIT-001 (105553) and 10PN-PD-DIT-007 (107046) studies. In 105553 study, subjects had been primed with 3 doses Prevenar vaccine at 2, 3 and 4 months of age co-administered with Infanrix related vaccines. In the 107046 study, subjects had received at 12-18 months of age a booster dose of Synflorix vaccine co-administered with Infanrix hexa vaccine. In this study, in the Year 4 (111347 study), subjects had received at Month 48 (4 years post Dose 1 in study 105553) one additional dose of Synflorix vaccine. In addition, subjects were also offered vaccination against hepatitis A (2 doses of Havrix and/or against varicella (a single dose of Varilrix).
Biological: GSK1024805A · Biological: Prevenar · Biological: Infanrix hexa · Biological: Havrix · Biological: Varilrix
This group consisted of subjects between, and including, 64-68 months of age at the time of additional vaccination (primed subjects) or dose 1 (unprimed subjects), and for whom the investigator believed that their parents/guardians could and would comply with the requirements of the protocol. Subjects were not previously vaccinated with any pneumococcal vaccine and received 2 doses of Synflorix vaccine at 64-68 and 66-70 months of age (at Day 0 and Month 2). The Unprimed Group was added only in Year 4 of the study.
Biological: GSK1024805A
No vaccination in this trial
Also known as: Synflorix
No vaccination in this trial
No vaccination in this trial
No vaccination in this trial
No vaccination in this trial
Number of Subjects With Anti-vaccine Pneumococcal Serotypes Antibody Concentrations Greater Than or Equal to (≥) the Cut-off [Follow-up Period: Persistence Analysis in Year 1 (111345 Sub-study)]
A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Analysis was performed using the 22F-inhibition Enzyme-linked immunosorbent assay (ELISA), using 0.05 microgram per milliliter (µg/mL) as seropositivity cut off.
Time frame: At Year 1 (Y1) (post booster vaccination administered in study 10PN-PD-DIT-007)
Number of Subjects With Anti-vaccine Pneumococcal Serotypes Antibody Concentrations ≥ the Cut-off [Follow-up Period: Persistence Analysis in Year 2 (111346 Sub-study)]
A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Analysis was performed using the 22F-inhibition Enzyme -linked immunosorbent assay (ELISA), using 0.05 μg/mL as seropositivity cut off.
Time frame: At Year 2 (Y2) (post booster vaccination administered in study 10PN-PD-DIT-007)
Number of Subjects With Anti-vaccine Pneumococcal Serotypes Antibody Concentrations ≥ the Cut-off [Follow-up Period: Persistence Analysis in Year 4 (111347 Sub-study)]
A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Analysis was performed using the 22F-inhibition Enzyme-linked immunosorbent assay (ELISA), using 0.05 μg/mL as seropositivity cut off.
Time frame: At Year 4 (Y4) (post booster vaccination administered in study 10PN-PD-DIT-007)
Antibody Concentrations Against Pneumococcal Serotypes [Follow-Up Period: Persistence Analysis in Year 1 (111345 Sub-study)]
Pneumococcal serotypes assessed were 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. Antibody concentrations against pneumococcal serotypes were determined as Geometric Mean Antibody Concentrations (GMC) and expressed as micro grams per milliliter (µg/mL).The seropositivity cut-off for the assay was ≥ 0.05 µg/mL.
Time frame: At Year 1 (Y1) (post booster vaccination administered in study 10PN-PD-DIT-007)
Antibody Concentrations Against Pneumococcal Serotypes [Follow-Up Period: Persistence Analysis in Year 2 (111346 Sub-study)]
Pneumococcal serotypes assessed were 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. Antibody concentrations against pneumococcal serotypes were determined as Geometric Mean Antibody Concentrations (GMC) and expressed as micro grams per milliliter (µg/mL). The seropositivity cut-off for the assay was ≥ 0.05 µg/mL.
Time frame: At Year 2 (Y2) (post booster vaccination administered in study 10PN-PD-DIT-007)
Antibody Concentrations Against Pneumococcal Serotypes [Follow-up Period: Persistence Analysis in Year 4 (111347 Sub-study)]
Pneumococcal serotypes assessed were serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. Antibody concentrations against pneumococcal serotypes were determined as Geometric Mean Antibody Concentrations (GMC) and expressed as micro grams per milliliter (µg/mL). The seropositivity cut-off for the assay was ≥ 0.05 μg/mL.
Time frame: At Year 4 (Y4) (post booster vaccination administered in study 10PN-PDDIT- 007)
Antibody Concentrations Against Pneumococcal Serotypes [Follow-up Period: Immunogenicity Analysis in Year 4 (111347 Sub-study)]
Anti-pneumococcal serotypes assessed were serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F . Antibody concentrations against pneumococcal serotypes were determined as Geometric Mean Antibody Concentrations (GMC) and expressed as micro grams per milliliter (µg/mL). The seropositivity cut-off for the assay was ≥ 0.05 μg/mL.
Time frame: For primed groups: At Month 48+7 days after additional dose (D7);For unprimed group: at Day 0 (D0) (Pre-vaccination [PRE]), at Day 7 (D7) post dose 1 (of the 2-dose catch-up vaccination) and at Month 3 (M3) post dose 2 (of the 2-dose catch-up vaccination)
Opsonophagocytic Activity (OPA) Titers Against Pneumococcal Serotypes [Follow-Up Period: Persistence Analysis in Year 1 (111345 Sub-study)]
Pneumococcal serotypes assessed were OPA-1, OPA-4, OPA-5, OPA-6B, OPA-7F, OPA-9V, OPA-14, OPA-18C, OPA-19F and OPA-23F. The seropositivity cut-off for the assay was ≥ 8. Opsonophagocytic activity was expressed as Geometric Mean Antibody Titers (GMT).
Time frame: At Year 1 (Y1) (post booster vaccination administered in study 10PN-PD-DIT-007)
Opsonophagocytic Activity (OPA) Titers Against Pneumococcal Serotypes [Follow-Up Period: Persistence Analysis in Year 2 (111346 Sub-study)]
Pneumococcal serotypes assessed were OPA-1, OPA-4, OPA-5, OPA-6B, OPA-7F, OPA-9V, OPA-14, OPA-18C, OPA-19F and OPA-23F. The seropositivity cut-off for the assay was ≥ 8. Opsonophagocytic activity was expressed as Geometric Mean Antibody Titers (GMT).
Time frame: At Year 2 (Y2) (post booster vaccination administrated in study 10PN-PD-DIT-007)
Opsonophagocytic Activity (OPA) Titers Against Pneumococcal Serotypes [Follow-up Period: Persistence Analysis in Year 4 (111347 Sub-study)]
Pneumococcal serotypes assessed were pneumococcal serotypes OPA-1, OPA-4, OPA-5, OPA-6B, OPA-7F, OPA-9V, OPA-14, OPA-18C, OPA-19F and OPA-23F. The seropositivity cut-off for the assay was ≥ 8. Opsonophagocytic activity was expressed as Geometric Mean Antibody Titers (GMT).
Time frame: At Year 4 (Y4) (post booster vaccination administrated in study 10PN-PD-DIT-007)
Opsonophagocytic Activity (OPA) Titers Against Pneumococcal Serotypes [Follow-up Period: Immunogenicity Analysis in Year 4 (111347 Sub-study)]
Pneumococcal serotypes assessed were OPA-1, OPA-4, OPA-5, OPA-6B, OPA-7F, OPA-9V, OPA-14, OPA-18C, OPA-19F and OPA-23F. The seropositivity cut-off for the assay was ≥ 8. Opsonophagocytic activity was expressed as Geometric Mean Antibody Titers (GMT).
Time frame: For primed groups: At Month 48+7 days after additional dose (D7);For unprimed group: at Day 0 (D0) (Pre-vaccination [PRE]), at Day 7 (D7) post dose 1 (of the 2-dose catch-up vaccination) and at Month 3 (M3) post dose 2 (of the 2-dose catch-up vaccination)
Antibody Concentrations Against Cross-reactive Pneumococcal Serotypes 6A and 19A (Anti-6A and - 19A) [Follow-up Period: Persistence Analysis in Year 1 (111345 Sub-study)]
The seropositivity cut-off for the assay was ≥ 0.05 μg/mL. Antibody concentrations against 6A and 19A pneumococcal serotypes were determined as Geometric Mean Antibody Concentrations (GMC) and expressed as micrograms per milliliter (µg/mL).
Time frame: At Year 1 (Y1) (post booster vaccination administered in study 10PN-PD-DIT-007)
Antibody Concentrations Against Cross-reactive Pneumococcal Serotypes 6A and 19A (Anti-6A and - 19A) - Follow-Up Period: Persistence Analysis in Year 2 (111346 Sub-study)
The seropositivity cut-off for the assay was ≥ 0.05 μg/mL. Antibody concentrations against 6A and 19A pneumococcal serotypes were determined as Geometric Mean Antibody Concentrations (GMC) and expressed as micrograms per milliliter (µg/mL).
Time frame: At Year 2 (Y2) (post booster vaccination administrated in study 10PN-PDDIT- 007)
Antibody Concentrations Against Cross-reactive Pneumococcal Serotypes 6A and 19A (Anti-6A and - 19A) [Follow-up Period: Persistence Analysis in Year 4 (111347 Sub-study)]
Antibody concentrations against 6A and 19A pneumococcal serotypes were determined as Geometric Mean Antibody Concentrations (GMC) and expressed as micro grams per milliliter (µg/mL). The seropositivity cut-off for the assay was ≥ 0.05 μg/mL.
Time frame: At Year 4 (Y4) (post booster vaccination administrated in study 10PN-PD-DIT- 007)
Antibody Concentrations Against Cross-reactive Pneumococcal Serotypes 6A and 19A (Anti-6A and 19A) [Follow-up Period: Immunogenicity Analysis in Year 4 (111347 Sub-study)]
Antibody concentrations against 6A and 19A pneumococcal serotypes were determined as Geometric Mean Antibody Concentrations (GMC) and expressed as micro grams per milliliter (µg/mL). The seropositivity cut-off for the assay was ≥ 0.05 μg/mL.
Time frame: For primed groups: At Month 48+7 days after additional dose (D7);For unprimed group: at Day 0 (D0) (Pre-vaccination [PRE]), at Day 7 (D7) post dose 1 (of the 2-dose catch-up vaccination) and at Month 3 (M3) post dose 2 (of the 2-dose catch-up vaccination)
Opsonophagocytic Activity (OPA) Titers Against Crossreactive Pneumococcal Serotypes 6A and 19 A [Follow-up Period: Persistence Analysis in Year 1 (111345 Sub-study)]
Opsonophagocytic activity were assessed for pneumococcal serotypes 6A and 19A (OPA-6A and OPA-19A). The seropositivity cut-off for the assay was ≥ 8. Opsonophagocytic activity was expressed as Geometric Mean Antibody Titers (GMT).
Time frame: At Year 1 (Y1) (post booster vaccination administered in study 10PN-PD-DIT-007)
Opsonophagocytic Activity (OPA) Titers Against Crossreactive Pneumococcal Serotypes 6A and 19 A [Follow-up Period: Persistence Analysis in Year 2 (111346 Sub-study)]
Opsonophagocytic activity were assessed for pneumococcal serotypes 6A and 19A (OPA-6A and OPA-19A). The seropositivity cut-off for the assay was ≥ 8. Opsonophagocytic activity was expressed as Geometric Mean Antibody Titers (GMT).
Time frame: At Year 2 (Y2) (post booster vaccination administrated in study 10PN-PD-DIT-007)
Opsonophagocytic Activity (OPA) Titers Against Crossreactive Pneumococcal Serotypes 6A and 19 A [Follow-up Period: Persistence Analysis in Year 4 (111347 Sub-study)]
Opsonophagocytic activity were assessed for pneumococcal serotypes 6A and 19A (OPA-6A and OPA-19A). The seropositivity cut-off for the assay was ≥ 8. Opsonophagocytic activity was expressed as Geometric Mean Antibody Titers (GMT).
Time frame: At Year 4 (Y4) (post booster vaccination administered in study 10PN-PD-DIT-007)
Opsonophagocytic Activity (OPA) Titers Against Pneumococcal Serotypes 6A and 19A [Follow-up Period: Immunogenicity Analysis in Year 4 (111347 Sub-study)]
Opsonophagocytic activity were assessed for pneumococcal serotypes 6A and 19A (OPA-6A and OPA-19A). The seropositivity cut-off for the assay was ≥ 8. Opsonophagocytic activity was expressed as Geometric Mean Antibody Titers (GMT).
Time frame: For primed groups: At Month 48+7 days after additional dose (D7);For unprimed group: at Day 0 (D0) (Pre-vaccination [PRE]), at Day 7 (D7) post dose 1 (of the 2-dose catch-up vaccination) and at Month 3 (M3) post dose 2 (of the 2-dose catch-up vaccination)
Antibody Concentrations to Protein D (Anti-PD) - Follow-up Period: Persistence Analysis in Year 1 (111345 Sub-study)
Anti-protein D (Anti-PD) antibody concentrations by Enzyme-Linked Immunosorbent Assay (ELISA) were calculated, expressed as geometric mean concentrations (GMCs) in ELISA unit per milli-liter (EL.U/mL) and tabulated. The seropositivity cut-off for the assay was ≥ 100 EL.U/mL.
Time frame: At Year 1 (Y1) (post booster vaccination administered in study 10PN-PD-DIT-007)
Antibody Concentrations to Protein D (Anti-PD) - Follow-up Period: Persistence Analysis in Year 2 (111346 Sub-study)
Anti-protein D (Anti-PD) antibody concentrations by Enzyme-Linked Immunosorbent Assay (ELISA) were calculated, expressed as geometric mean concentrations (GMCs) in ELISA unit per milli-liter (EL.U/mL) and tabulated. The seropositivity cut-off for the assay was ≥ 100 EL.U/mL.
Time frame: At Year 2 (Y2) (post booster vaccination administered in study 10PN-PD-DIT- 007)
Antibody Concentrations to Protein D (Anti-PD) [Follow-up Period: Persistence Analysis in Year 4 (111347 Sub-study)]
Anti-protein D (Anti-PD) antibody concentrations by Enzyme-Linked Immunosorbent Assay (ELISA) were calculated, expressed as geometric mean concentrations (GMCs) in ELISA unit per milli-liter (EL.U/mL) and tabulated. The seropositivity cut-off for the assay was ≥ 100 EL.U/mL.
Time frame: At Year 4 (Y4) (post booster vaccination administered in study 10PN-PD-DIT- 007)
Antibody Concentrations to Protein D (Anti-PD) [Follow-up Period: Immunogenicity Analysis in Year 4 (111347 Sub-study)]
Anti-protein D (Anti-PD) antibody concentrations by Enzyme-Linked Immunosorbent Assay (ELISA) were calculated, expressed as geometric mean concentrations (GMCs) in ELISA unit per milli-liter (EL.U/mL) and tabulated. The seropositivity cut-off for the assay was ≥ 100 EL.U/mL.
Time frame: For primed groups: At Month 48+7 days after additional dose (D7);For unprimed group: at Day 0 (D0) (Pre-vaccination [PRE]), at Day 7 (D7) post dose 1 (of the 2-dose catch-up vaccination) and at Month 3 (M3) post dose 2 (of the 2-dose catch-up vaccination)
Number of Subjects Reported With Solicited Local Symptoms
Solicited local symptoms assessed were pain, redness and swelling. Any occurrence of symptom regardless of intensity grade. Any Redness or any Swelling symptom = any symptom greater than (\>) 0 millimeter (mm). Grade 3 pain = maximum intensity of local injection defined as subject crying when limb was moved/spontaneously painful. Grade 3 redness/swelling= maximum intensity of local injection \>30 mm. Follow-up period was of 4 days (Days 0-3) after Synflorix vaccination in Year 4 Persistence and Immunological Memory 111347 Study, thus one period of 4 days for primed subjects and 2 periods of 4 days for unprimed subjects.
Time frame: Within 4 days (Days 0-3) period(s) after Synflorix vaccination in Year 4 Persistence and Immunological Memory 111347 Study
Number of Subjects Reported With Solicited General Symptoms
Solicited general symptoms assessed were drowsiness, irritability, loss of appetite and fever (any fever defined as temperature by axillary measurement of 37.5°C and above). Grade 3 drowsiness was defined as drowsiness that prevented normal activity; Grade 3 irritability was defined as crying that could not be comforted/prevented normal activity. Grade 3 loss of appetite was defined as subject not eating at all. Grade 3 fever was defined as axillary temperature \>39.5°C. Related AE was defined as any AE assessed by investigators to be causally related to administration of the study vaccine. Follow-up period was of 4 days (Days 0-3) after Synflorix vaccination in Year 4 Persistence and Immunological Memory 111347 Study, thus one period of 4 days for primed subjects and 2 periods of 4 days for unprimed subjects.
Time frame: Within 4 days (Days 0-3) period(s) after Synflorix vaccination in Year 4 Persistence and Immunological Memory 111347 Study
Number of Subjects With Unsolicited Adverse Events (AEs)
An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. "Any" was defined an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination. Follow-up period was of 31 days (Days 0-30) after Synflorix vaccination in Year 4 Persistence and Immunological Memory 111347 Study, thus one period of 31 days for primed subjects and 2 periods of 31 days for unprimed subjects.
Time frame: Within 31 days (Day 0-30) after Synflorix vaccination in Year 4 Persistence and Immunological Memory 111347 Study
Number of Subjects With Serious Adverse Events (SAEs) Related to Study Procedures [Follow-up Period: Year 1 (111345 Sub-study)]
An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or may evolve into one of the outcomes listed above. "Any" was defined an incidence of a SAE regardless of intensity/severity.
Time frame: During Year 1 (Y1) (post booster vaccination administered in study 10PN-PD-DIT-007) i.e. for each primed subject: from the time the subject was enrolled in the 111345 study until he/she completed the same study (approximatively 12 months)
Number of Subjects With Serious Adverse Events (SAEs) Related to Study Procedures [(Follow-up Period: Year 2 (111346 Sub-study) Until Year 4 (111347 Sub-study)]
An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or may evolve into one of the outcomes listed above. "Any" is defined an incidence of a SAE regardless of intensity/severity.
Time frame: From Year (Y) 2 to Y4 FU visit (post booster vaccination administered in 10PN-PD-DIT-007) i.e. for each subject(S): when S was enrolled in 111346 study until S completed the same study visit or the 111347 study visit (range of 1 to 3 years for each S))
Number of Subjects With Serious Adverse Events (SAEs) [Follow-up Period: Vaccination Period in Year 4 (111347 Sub-study)]
An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or may evolve into one of the outcomes listed above. "Any" is defined an incidence of a SAE regardless of intensity/severity.
Time frame: For primed groups: from Months 48-49 (additional vaccination period); for unprimed group: from Day 0 up to Month 3 (catch-up vaccination period)
Number of Seropositive Subjects for Opsonophagocytic Activity Against Pneumococcal Serotypes [Follow-up Period: Persistence Analysis in Year 1 (111345 Sub-study)]
A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Pneumococcal serotypes assessed were 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. The seropositivity cut-off for the assay was 8.
Time frame: At Year 1 (Y1) (post booster vaccination administered in study 10PN-PD-DIT-007)
Number of Seropositive Subjects for Opsonophagocytic Activity Against Pneumococcal Serotypes [Follow-up Period: Persistence Analysis in Year 2 (111346 Sub-study)]
A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Pneumococcal serotypes assessed were 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. The seropositivity cut-off for the assay was 8.
Time frame: At Year 2 (Y2) (post booster vaccination administered in study 10PN-PD-DIT-007)
Number of Seropositive Subjects for Opsonophagocytic Activity Against Pneumococcal Serotypes [Follow-up Period: Persistence Analysis in Year 4 (111347 Sub-study)]
A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Pneumococcal serotypes assessed were 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. The seropositivity cut-off for the assay was 8.
Time frame: At Year 4 (Y4) (post booster vaccination administered in study 10PN-PD-DIT-007)
Number of Seropositive Subjects for Opsophagocytic Activity Against Pneumococcal Serotypes [Follow-up Period: Immunogenicity Analysis in Year 4 (111347 Sub-study)]
A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Pneumococcal serotypes assessed were 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. Analysis was performed with Unprimed group included. The seropositivity cut-off for the assay was 8.
Time frame: For primed groups: At Month 48+7 days after additional dose (D7);For unprimed group: at Day 0 (D0) (Pre-vaccination [PRE]), at Day 7 (D7) post dose 1 (of the 2-dose catch-up vaccination) and at Month 3 (M3) post dose 2 (of the 2-dose catch-up vaccination)
Number of Seropositive Subjects for Anti-pneumococcal Cross-reactive Serotypes 6A and 19A [Follow-up Period: Persistence Analysis in Year 1 (111345 Sub-study)]
A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Pneumococcal serotypes assessed were 6A and 19A. The results for the immune responses were measured by 22F-inhibition ELISA. The seropositivity cut-off for the assay was 0.05 μg/mL.
Time frame: At Year 1 (Y1) (post booster vaccination administered in study 10PN-PD-DIT-007)
Number of Seropositive Subjects for Anti-pneumococcal Cross-reactive Serotypes 6A and 19A [Follow-up Period: Persistence Analysis in Year 2 (111346 Sub-study)]
A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Pneumococcal serotypes assessed were 6A and 19A. The immune responses were measured by 22F-inhibation ELISA. The seropositivity cut-off for the assay was 0.05 μg/mL.
Time frame: At Year 2 (Y2) (post booster vaccination administered in study 10PN-PD-DIT-007)
Number of Seropositive Subjects for Anti-pneumococcal Cross-reactive Serotypes 6A and 19A [Follow-up Period: Persistence Analysis in Year 4 (111347 Sub-study)]
A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Pneumococcal serotypes assessed were 6A and 19A. The immune responses were measured by 22F-inhibition ELISA. The seropositivity cut-off for the assay was 0.05 μg/mL.
Time frame: At Year 4 (Y4) (post booster vaccination administered in study 10PN-PD-DIT-007)
Number of Seropositive Subjects for Anti-pneumococcal Cross-reactive Serotypes 6A and 19A [Follow-up Period: Immunogenicity Analysis in Year 4 (111347 Sub-study)]
A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Pneumococcal serotypes assessed were 6A and 19A. The immune responses were measured by 22F-inhibition ELISA. The seropositivity cut-off for the assay was 0.05 μg/mL.
Time frame: For primed groups: At Month 48+7 days after additional dose (D7);For unprimed group: at Day 0 (D0) (Pre-vaccination [PRE]), at Day 7 (D7) post dose 1 (of the 2-dose catch-up vaccination) and at Month 3 (M3) post dose 2 (of the 2-dose catch-up vaccination)
Number of Seropositive Subjects for Opsonophagocytic Activity Against Pneumococcal Cross-reactive Serotypes 6A and 19A [Follow-up Period: Persistence Analysis in Year 1 (111345 Sub-study)]
A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Pneumococcal serotypes assessed were 6A and 19A. The immune responses were mesured by Opsonophagocytic activity (OPA). The seropositivity cut-off for the assay was 8.
Time frame: At Year 1 (Y1) (post booster vaccination administered in study 10PN-PD-DIT-007)
Number of Seropositive Subjects for Opsonophagocytic Activity Against Pneumococcal Cross-reactive Serotypes 6A and 19A [Follow-up Period: Persistence Analysis in Year 2 (111346 Sub-study)]
A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Pneumococcal serotypes assessed were 6A and 19A. The immune responses were measured by Opsonophagocytic activity (OPA). The seropositivity cut-off for the assay was 8.
Time frame: At Year 2 (Y2) (post booster vaccination administered in study 10PN-PD-DIT-007)
Number of Seropositive Subjects for Opsonophagocytic Activity Against Pneumococcal Cross-reactive Serotypes 6A and 19A [Follow-up Period: Persistence Analysis in Year 4 (111347 Sub-study)]
A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Pneumococcal serotypes assessed were 6A and 19A. The immune responses were measured by Opsonophagocytic Activity (OPA). The seropositivity cut-off for the assay was 8.
Time frame: At Year 4 (Y4) (post booster vaccination administered in study 10PN-PD-DIT-007)
Number of Seropositive Subjects for Opsonophagocytic Activity Against Pneumococcal Cross-reactive Serotypes 6A and 19A [Follow-up Period: Immunogenicity Analysis in Year 4 (111347 Sub-study)]
A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Pneumococcal serotypes assessed were 6A and 19A. The immune responses were measured by Opsonophagocytic Activity (OPA). The seropositivity cut-off for the assay was 8.
Time frame: For primed groups: At Month 48+7 days after additional dose (D7);For unprimed group: at Day 0 (D0) (Pre-vaccination [PRE]), at Day 7 (D7) post dose 1 (of the 2-dose catch-up vaccination) and at Month 3 (M3) post dose 2 (of the 2-dose catch-up vaccination)
Number of Seropositive Subjects for Anti-protein D (Anti-PD) [Follow-up Period: Persistence Analysis in Year 1 (111345 Sub-study)]
A seropositive subject was a subject whose anti-PD antibody concentration was greater than or equal to (≥) the cut-off value. The seropositivity cut-off for the assay was 100 EL.U/ML.
Time frame: At Year 1 (Y1) (post booster vaccination administered in study 10PN-PD-DIT-007)
Number of Seropositive Subjects for Anti Protein D (Anti-PD) [Follow-up Period: Persistence Analysis in Year 2 (111345 Sub-study)]
A seropositive subject was a subject whose anti-PD antibody concentration was greater than or equal to (≥) the cut-off value. The seropositivity cut-off for the assay was 100 EL.U/ML.
Time frame: At Year 2 (Y2) (post booster vaccination administered in study 10PN-PD-DIT-007)
Number of Seropositive Subjects for Anti-protein D (Anti-PD) [Follow-up Period: Persistence Analysis in Year 4 (111347 Sub-study)]
A seropositive subject was a subject whose anti-PD antibody concentration was greater than or equal to (≥) the cut-off value. The seropositivity cut-off for the assay was 100 EL.U/ML.
Time frame: At Year 4 (Y4) (post booster vaccination administered in study 10PN-PD-DIT-007)
Number of Seropositive Subjects for Anti-protein D (Anti-PD) [Follow-up Period: Immunogenicity Analysis in Year 4 (111347 Sub-study)]
A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. The seropositivity cut-off for the assay was 100 EL.U/ML.
Time frame: For primed groups: At Month 48+7 days after additional dose (D7);For unprimed group: at Day 0 (D0) (Pre-vaccination [PRE]), at Day 7 (D7) post dose 1 (of the 2-dose catch-up vaccination) and at Month 3 (M3) post dose 2 (of the 2-dose catch-up vaccination)
Number of Seropositive Subjects for Anti-vaccine Pneumococcal Serotypes Antibodies [Follow-up Period: Immunogenicity Analysis in Year 4 (111347 Sub-study)]
A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Analysis was performed using the 22F-inhibition Enzyme-linked immunosorbent assay (ELISA), using 0.05 microgram per milliliter (µg/mL) as seropositivity cut off.
Time frame: For primed groups: At Month 48+7 days after additional dose (D7);For unprimed group: at Day 0 (D0) (Pre-vaccination [PRE]), at Day 7 (D7) post dose 1 (of the 2-dose catch-up vaccination) and at Month 3 (M3) post dose 2 (of the 2-dose catch-up vaccination)
Primed groups included Synflorix vaccinated subjects in study 10PN-PD-DIT-007. The Unprimed Group, added only in Year 4,included subjects unprimed with any pneumococcal vaccine age-matched with primed groups. The study included 3 sub-studies (111345, 111346, 111347) corresponding to Year 1, 2 and 4 time points post Dose 1 in Study 10PN-PD-DIT-001.
| Milestone | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix | Unprimed Group |
|---|---|---|---|---|
| Started | 391 | 31 | 102 | 0 |
| Completed | 391 | 31 | 102 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix | Unprimed Group |
|---|---|---|---|---|
| Started | 370 | 31 | 96 | 0 |
| Completed | 370 | 31 | 96 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix | Unprimed Group |
|---|---|---|---|---|
| Started | 264 | 20 | 65 | 100 |
| Completed | 263 | 19 | 64 | 100 |
| Not completed | 1 | 1 | 1 | 0 |
| Withdrew: Parents decision | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 | 0 | 0 |
A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Analysis was performed using the 22F-inhibition Enzyme-linked immunosorbent assay (ELISA), using 0.05 microgram per milliliter (µg/mL) as seropositivity cut off.
| Participants | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix |
|---|---|---|---|
| Anti-1 antibodies, Y1 | 372 | 7 | 99 |
| Anti-4 antibodies, Y1 | 384 | 31 | 102 |
| Anti-5 antibodies, Y1 | 386 | 19 | 101 |
| Anti-6B antibodies, Y1 | 384 | 31 | 100 |
| Anti-7F antibodies, Y1 | 387 | 17 | 102 |
| Anti-9V antibodies, Y1 | 388 | 17 | 102 |
| Anti-14 antibodies, Y1 | 387 | 31 | 102 |
| Anti-18C antibodies, Y1 | 384 | 31 | 102 |
| Anti-19F antibodies, Y1 | 387 | 31 | 102 |
| Anti-23F antibodies, Y1 | 386 | 31 | 102 |
A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Analysis was performed using the 22F-inhibition Enzyme -linked immunosorbent assay (ELISA), using 0.05 μg/mL as seropositivity cut off.
| Participants | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix |
|---|---|---|---|
| Anti-1 antibodies, Y2 | 354 | 18 | 90 |
| Anti-4 antibodies, Y2 | 356 | 30 | 96 |
| Anti-5 antibodies, Y2 | 362 | 21 | 95 |
| Anti-6B antibodies, Y2 | 355 | 30 | 95 |
| Anti-7F antibodies, Y2 | 367 | 19 | 95 |
| Anti-9V antibodies, Y2 | 362 | 30 | 96 |
| Anti-14 antibodies, Y2 | 367 | 30 | 96 |
| Anti-18C antibodies, Y2 | 365 | 30 | 96 |
| Anti-19F antibodies, Y2 | 368 | 30 | 95 |
| Anti-23F antibodies, Y2 | 357 | 30 | 95 |
A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Analysis was performed using the 22F-inhibition Enzyme-linked immunosorbent assay (ELISA), using 0.05 μg/mL as seropositivity cut off.
| Participants | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix |
|---|---|---|---|
| Anti-1 antibodies, Y4 | 238 | 14 | 71 |
| Anti-4 antibodies, Y4 | 238 | 18 | 72 |
| Anti-5 antibodies, Y4 | 257 | 19 | 73 |
| Anti-6B antibodies, Y4 | 258 | 19 | 74 |
| Anti-7F antibodies, Y4 | 260 | 13 | 73 |
| Anti-9V antibodies, Y4 | 255 | 19 | 75 |
| Anti-14 antibodies, Y4 | 263 | 19 | 75 |
| Anti-18C antibodies, Y4 | 256 | 19 | 73 |
| Anti-19F antibodies, Y4 | 260 | 19 | 75 |
| Anti-23F antibodies, Y4 | 254 | 19 | 74 |
Pneumococcal serotypes assessed were 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. Antibody concentrations against pneumococcal serotypes were determined as Geometric Mean Antibody Concentrations (GMC) and expressed as micro grams per milliliter (µg/mL).The seropositivity cut-off for the assay was ≥ 0.05 µg/mL.
| µg/mL | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix |
|---|---|---|---|
| Anti-1 antibodies, Y1 | 0.29 (0.27 to 0.32) | 0.04 (0.03 to 0.06) | 0.26 (0.21 to 0.31) |
| Anti-4 antibodies, Y1 | 0.5 (0.45 to 0.55) | 0.59 (0.46 to 0.75) | 1.01 (0.84 to 1.21) |
| Anti-5 antibodies, Y1 | 0.59 (0.54 to 0.65) | 0.07 (0.05 to 0.11) | 0.42 (0.35 to 0.52) |
| Anti-6B antibodies, Y1 | 0.52 (0.45 to 0.6) | 0.98 (0.63 to 1.53) | 0.54 (0.42 to 0.69) |
| Anti-7F antibodies, Y1 | 0.71 (0.66 to 0.77) | 0.08 (0.05 to 0.13) | 0.83 (0.7 to 0.99) |
| Anti-9V antibodies, Y1 | 0.79 (0.71 to 0.89) | 0.93 (0.7 to 1.22) | 0.58 (0.49 to 0.68) |
| Anti-14 antibodies, Y1 | 1.27 (1.12 to 1.44) | 1.79 (1.29 to 2.48) | 1.47 (1.17 to 1.85) |
| Anti-18C antibodies, Y1 | 0.88 (0.81 to 0.96) | 0.91 (0.71 to 1.16) | 0.82 (0.69 to 0.98) |
| Anti-19F antibodies, Y1 | 1.43 (1.27 to 1.6) | 0.83 (0.47 to 1.45) | 1.51 (1.19 to 1.92) |
| Anti-23F antibodies, Y1 | 0.61 (0.54 to 0.69) | 1.18 (0.84 to 1.68) | 0.7 (0.56 to 0.88) |
Pneumococcal serotypes assessed were 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. Antibody concentrations against pneumococcal serotypes were determined as Geometric Mean Antibody Concentrations (GMC) and expressed as micro grams per milliliter (µg/mL). The seropositivity cut-off for the assay was ≥ 0.05 µg/mL.
| µg/mL | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix |
|---|---|---|---|
| Anti-1 antibodies, Y2 | 0.19 (0.17 to 0.21) | 0.07 (0.05 to 0.1) | 0.17 (0.14 to 0.2) |
| Anti-4 antibodies, Y2 | 0.27 (0.24 to 0.3) | 0.3 (0.24 to 0.38) | 0.52 (0.43 to 0.64) |
| Anti-5 antibodies, Y2 | 0.41 (0.37 to 0.45) | 0.09 (0.06 to 0.13) | 0.33 (0.27 to 0.41) |
| Anti-6B antibodies, Y2 | 0.7 (0.58 to 0.83) | 0.99 (0.57 to 1.71) | 0.9 (0.63 to 1.29) |
| Anti-7F antibodies, Y2 | 0.53 (0.48 to 0.58) | 0.1 (0.06 to 0.16) | 0.59 (0.49 to 0.71) |
| Anti-9V antibodies, Y2 | 0.64 (0.54 to 0.75) | 0.61 (0.37 to 1) | 0.5 (0.37 to 0.68) |
| Anti-14 antibodies, Y2 | 1.73 (1.48 to 2.02) | 1.94 (1.12 to 3.36) | 1.7 (1.25 to 2.31) |
| Anti-18C antibodies, Y2 | 0.54 (0.48 to 0.62) | 0.59 (0.39 to 0.88) | 0.48 (0.38 to 0.59) |
| Anti-19F antibodies, Y2 | 2.16 (1.77 to 2.65) | 0.99 (0.51 to 1.91) | 2.41 (1.67 to 3.46) |
| Anti-23F antibodies, Y2 | 0.68 (0.56 to 0.82) | 1.24 (0.83 to 1.85) | 0.64 (0.48 to 0.86) |
Pneumococcal serotypes assessed were serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. Antibody concentrations against pneumococcal serotypes were determined as Geometric Mean Antibody Concentrations (GMC) and expressed as micro grams per milliliter (µg/mL). The seropositivity cut-off for the assay was ≥ 0.05 μg/mL.
| μg/mL | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix |
|---|---|---|---|
| Anti-1 antibodies, Y4 | 0.2 (0.17 to 0.24) | 0.17 (0.07 to 0.43) | 0.23 (0.17 to 0.32) |
| Anti-4 antibodies, Y4 | 0.19 (0.16 to 0.22) | 0.23 (0.12 to 0.41) | 0.31 (0.25 to 0.38) |
| Anti-5 antibodies, Y4 | 0.36 (0.31 to 0.4) | 0.19 (0.1 to 0.35) | 0.35 (0.28 to 0.43) |
| Anti-6B antibodies, Y4 | 1.3 (1.1 to 1.55) | 1.19 (0.68 to 2.07) | 0.97 (0.74 to 1.27) |
| Anti-7F antibodies, Y4 | 0.44 (0.38 to 0.52) | 0.16 (0.08 to 0.36) | 0.49 (0.37 to 0.65) |
| Anti-9V antibodies, Y4 | 1.17 (0.92 to 1.47) | 1.19 (0.43 to 3.27) | 0.67 (0.46 to 0.99) |
| Anti-14 antibodies, Y4 | 3.66 (3.01 to 4.45) | 2.57 (1.22 to 5.42) | 2.94 (2.11 to 4.12) |
| Anti-18C antibodies, Y4 | 0.7 (0.58 to 0.84) | 0.87 (0.4 to 1.88) | 0.63 (0.45 to 0.89) |
| Anti-19F antibodies, Y4 | 4.17 (3.4 to 5.1) | 4.74 (2.24 to 10) | 4.05 (3.03 to 5.41) |
| Anti-23F antibodies, Y4 | 1.57 (1.26 to 1.96) | 1.64 (1.15 to 2.34) | 1.12 (0.79 to 1.58) |
Anti-pneumococcal serotypes assessed were serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F . Antibody concentrations against pneumococcal serotypes were determined as Geometric Mean Antibody Concentrations (GMC) and expressed as micro grams per milliliter (µg/mL). The seropositivity cut-off for the assay was ≥ 0.05 μg/mL.
| μg/mL | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix | Unprimed Group |
|---|---|---|---|---|
| Anti-1 antibodies, PRE | — | — | — | 0.1 (0.08 to 0.13) |
| Anti-1 antibodies, D7 | 5.36 (4.54 to 6.33) | 3.04 (1.22 to 7.56) | 5 (3.72 to 6.71) | 1.35 (1.08 to 1.69) |
| Anti-1 antibodies, M3 | — | — | — | 2.39 (2.06 to 2.78) |
| Anti-4 antibodies, PRE | — | — | — | 0.04 (0.03 to 0.05) |
| Anti-4 antibodies, D7 | 12.11 (10.08 to 14.54) | 10.45 (6.49 to 16.81) | 7.13 (5.18 to 9.82) | 4.74 (3.77 to 5.95) |
| Anti-4 antibodies, M3 | — | — | — | 7.32 (6.7 to 8) |
| Anti-5 antibodies, PRE | — | — | — | 0.1 (0.08 to 0.12) |
| Anti-5 antibodies, D7 | 6.23 (5.19 to 7.49) | 3.24 (1.44 to 7.29) | 8.15 (5.71 to 11.63) | 1.2 (0.97 to 1.49) |
| Anti-5 antibodies, M3 | — | — | — | 3.1 (2.7 to 3.55) |
| Anti-6B antibodies, PRE | — | — | — | 0.21 (0.15 to 0.29) |
| Anti-6B antibodies, D7 | 3.68 (3.16 to 4.29) | 2.85 (1.89 to 4.3) | 2.15 (1.62 to 2.85) | 0.53 (0.4 to 0.71) |
| Anti-6B antibodies, M3 | — | — | — | 1.25 (1.01 to 1.54) |
| Anti-7F antibodies, PRE | — | — | — | 0.12 (0.09 to 0.16) |
| Anti-7F antibodies, D7 | 7.16 (6.11 to 8.39) | 3.26 (1.67 to 6.35) | 7.57 (5.84 to 9.81) | 1.67 (1.33 to 2.09) |
| Anti-7F antibodies, M3 | — | — | — | 4.55 (3.93 to 5.26) |
| Anti-9V antibodies, PRE | — | — | — | 0.19 (0.12 to 0.28) |
| Anti-9V antibodies, D7 | 9.94 (8.59 to 11.51) | 9 (5.49 to 14.77) | 5.32 (4.08 to 6.94) | 0.9 (0.66 to 1.23) |
| Anti-9V antibodies, M3 | — | — | — | 2.2 (1.85 to 2.62) |
| Anti-14 antibodies, PRE | — | — | — | 0.58 (0.38 to 0.87) |
| Anti-14 antibodies, D7 | 19.38 (16.74 to 22.43) | 13.26 (6.91 to 25.43) | 18.61 (14.23 to 24.34) | 1.72 (1.2 to 2.46) |
| Anti-14 antibodies, M3 | — | — | — | 7.81 (6.34 to 9.63) |
| Anti-18C antibodies, PRE | — | — | — | 0.1 (0.07 to 0.15) |
| Anti-18C antibodies, D7 | 15.51 (13.06 to 18.43) | 19.71 (11.87 to 32.74) | 13.34 (9.34 to 19.05) | 2.26 (1.66 to 3.09) |
| Anti-18C antibodies, M3 | — | — | — | 13.21 (11.44 to 15.25) |
| Anti-19F antibodies, PRE | — | — | — | 0.6 (0.4 to 0.89) |
| Anti-19F antibodies, D7 | 11.63 (10 to 13.51) | 16.44 (10.68 to 25.29) | 8.09 (6.29 to 10.42) | 5.12 (3.97 to 6.62) |
| Anti-19F antibodies, M3 | — | — | — | 15.47 (13.08 to 18.29) |
| Anti-23F antibodies, PRE | — | — | — | 0.1 (0.07 to 0.14) |
| Anti-23F antibodies, D7 | 6.5 (5.61 to 7.53) | 9.34 (5.62 to 15.54) | 4.7 (3.43 to 6.45) | 0.42 (0.3 to 0.59) |
| Anti-23F antibodies, M3 | — | — | — | 1.63 (1.32 to 2.01) |
Pneumococcal serotypes assessed were OPA-1, OPA-4, OPA-5, OPA-6B, OPA-7F, OPA-9V, OPA-14, OPA-18C, OPA-19F and OPA-23F. The seropositivity cut-off for the assay was ≥ 8. Opsonophagocytic activity was expressed as Geometric Mean Antibody Titers (GMT).
| Titer | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix |
|---|---|---|---|
| Anti-1 OPA Titers, Y1 | 16.2 (13.8 to 19) | 4.8 (3.6 to 6.4) | 7.3 (5.9 to 9) |
| Anti-4 OPA Titers, Y1 | 59.8 (45.7 to 78.3) | 192.9 (82.4 to 452) | 88.9 (54.6 to 144.6) |
| Anti-5 OPA Titers, Y1 | 24.2 (20.8 to 28.2) | 5.1 (3.6 to 7.4) | 11.2 (8.7 to 14.3) |
| Anti-6B OPA Titers, Y1 | 35.5 (26.5 to 47.5) | 476.9 (175.3 to 1298) | 44.7 (24 to 83.3) |
| Anti-7F OPA Titers, Y1 | 1855.7 (1644.4 to 2094.1) | 350.4 (121.8 to 1008) | 1617.2 (1152.9 to 2268.3) |
| Anti-9V OPA Titers, Y1 | 791.5 (701.8 to 892.8) | 1240.7 (829.4 to 1855.9) | 370.5 (281.8 to 487.2) |
| Anti-14 OPA Titers, Y1 | 551.9 (486.5 to 626.2) | 607.3 (385.3 to 957.1) | 456.6 (361.1 to 577.3) |
| Anti-18C OPA Titers, Y1 | 23.5 (18.6 to 29.8) | 15.5 (6.1 to 39.2) | 10.4 (7.1 to 15.4) |
| Anti-19F OPA Titers, Y1 | 53.4 (44.7 to 63.9) | 35.4 (15.9 to 78.6) | 58 (41.6 to 80.7) |
| Anti-23F OPA Titers, Y1 | 784.9 (625.4 to 985) | 3013.1 (1349.5 to 6727.2) | 552.3 (362.1 to 842.5) |
Pneumococcal serotypes assessed were OPA-1, OPA-4, OPA-5, OPA-6B, OPA-7F, OPA-9V, OPA-14, OPA-18C, OPA-19F and OPA-23F. The seropositivity cut-off for the assay was ≥ 8. Opsonophagocytic activity was expressed as Geometric Mean Antibody Titers (GMT).
| Titer | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix |
|---|---|---|---|
| Anti-1 OPA Titers, Y2 | 8.4 (7.3 to 9.7) | 4 (4 to 4) | 6.3 (4.9 to 8) |
| Anti-4 OPA Titers, Y2 | 29 (22.1 to 38) | 33.5 (11.9 to 94.6) | 39.3 (23.7 to 65.2) |
| Anti-5 OPA Titers, Y2 | 11.4 (10 to 13) | 4.3 (3.9 to 4.7) | 7.4 (6 to 9.1) |
| Anti-6B OPA Titers, Y2 | 167.2 (124.1 to 225.2) | 526.1 (210.5 to 1314.4) | 213.7 (117.8 to 387.6) |
| Anti-7F OPA Titers, Y2 | 1488.7 (1358.3 to 1631.6) | 1068.3 (619.5 to 1842.4) | 1387.8 (1096.2 to 1756.9) |
| Anti-9V OPA Titers, Y2 | 648.5 (570 to 737.7) | 730.4 (457.7 to 1165.7) | 391 (279.2 to 547.5) |
| Anti-14 OPA Titers, Y2 | 660.2 (567.2 to 768.4) | 651 (348.6 to 1215.5) | 534.4 (381.6 to 748.4) |
| Anti-18C OPA Titers, Y2 | 34.9 (26.6 to 45.7) | 34.8 (11.7 to 103.2) | 17.7 (10.7 to 29.2) |
| Anti-19F OPA Titers, Y2 | 78.1 (60.9 to 100.2) | 49.2 (21.2 to 113.9) | 105.4 (65.8 to 168.7) |
| Anti-23F OPA Titers, Y2 | 632 (483 to 827) | 1923 (952.2 to 3883.7) | 435 (250.5 to 755.5) |
Pneumococcal serotypes assessed were pneumococcal serotypes OPA-1, OPA-4, OPA-5, OPA-6B, OPA-7F, OPA-9V, OPA-14, OPA-18C, OPA-19F and OPA-23F. The seropositivity cut-off for the assay was ≥ 8. Opsonophagocytic activity was expressed as Geometric Mean Antibody Titers (GMT).
| Titer | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix |
|---|---|---|---|
| Anti-1 OPA Titers, Y4 | 8.8 (7.1 to 10.9) | 4.6 (3.4 to 6.4) | 8.9 (5.9 to 13.2) |
| Anti-4 OPA Titers, Y4 | 37.9 (27.2 to 52.8) | 62.2 (13.6 to 284.7) | 50.7 (26.5 to 97) |
| Anti-5 OPA Titers, Y4 | 7.7 (6.8 to 8.9) | 5.3 (3.5 to 8.1) | 5.5 (4.5 to 6.6) |
| Anti-6B OPA Titers, Y4 | 875.7 (658.7 to 1164.3) | 978.3 (395.3 to 2421.3) | 716.4 (417.4 to 1229.7) |
| Anti-7F OPA Titers, Y4 | 1693.1 (1489.3 to 1924.8) | 965.8 (666.8 to 1398.9) | 1602.1 (1286.9 to 1994.5) |
| Anti-9V OPA Titers, Y4 | 747.4 (624.9 to 894.1) | 563.8 (220.2 to 1444) | 558.6 (403 to 774.2) |
| Anti-14 OPA Titers, Y4 | 1139.8 (961.9 to 1350.5) | 687.9 (267.8 to 1767.4) | 849.4 (645.4 to 1117.8) |
| Anti-18C OPA Titers, Y4 | 46.4 (33.3 to 64.5) | 35.3 (8.8 to 142.5) | 26.6 (14.3 to 49.3) |
| Anti-19F OPA Titers, Y4 | 151.7 (115.9 to 198.4) | 178.8 (64.6 to 495.1) | 129.3 (83.1 to 201.4) |
| Anti-23F OPA Titers, Y4 | 1518.4 (1107.9 to 2080.9) | 3366.1 (1599.2 to 7085.1) | 1146.2 (596.8 to 2201.3) |
Pneumococcal serotypes assessed were OPA-1, OPA-4, OPA-5, OPA-6B, OPA-7F, OPA-9V, OPA-14, OPA-18C, OPA-19F and OPA-23F. The seropositivity cut-off for the assay was ≥ 8. Opsonophagocytic activity was expressed as Geometric Mean Antibody Titers (GMT).
| Titers | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix | Unprimed Group |
|---|---|---|---|---|
| Anti-1 OPA Titers, PRE | — | — | — | 5 (4.2 to 5.9) |
| Anti-1 OPA Titers, D7 | 2920.8 (2353.5 to 3624.7) | 1331 (586.7 to 3019.5) | 1816.1 (1090 to 3025.8) | 605 (462.7 to 791.2) |
| Anti-1 OPA Titers, M3 | — | — | — | 128.3 (97.3 to 169.1) |
| Anti-4 OPA Titers, PRE | — | — | — | 11.5 (7.2 to 18.3) |
| Anti-4 OPA Titers, D7 | 23633.7 (19118.5 to 29215.3) | 10650.3 (3969.2 to 28577.6) | 8592.8 (5609.3 to 13163.1) | 18262.1 (15571.6 to 21417.4) |
| Anti-4 OPA Titers, M3 | — | — | — | 4451.3 (3962.4 to 5000.6) |
| Anti-5 OPA Titers, PRE | — | — | — | 4.9 (4.3 to 5.7) |
| Anti-5 OPA Titers, D7 | 822.3 (662.7 to 1020.3) | 375.6 (217.4 to 648.9) | 683.6 (428.6 to 1090.2) | 295.6 (219.4 to 398.3) |
| Anti-5 OPA Titers, M3 | — | — | — | 93.2 (73.7 to 117.8) |
| Anti-6B OPA Titers, PRE | — | — | — | 70.7 (33.5 to 149.2) |
| Anti-6B OPA Titers, D7 | 3513.1 (2858.1 to 4318.1) | 3566.6 (2446.1 to 5200.3) | 1590.5 (942.8 to 2683.3) | 1971.4 (1238 to 3139.2) |
| Anti-6B OPA Titers, M3 | — | — | — | 2536.9 (2014.1 to 3195.5) |
| Anti-7F OPA Titers, PRE | — | — | — | 1368.2 (849.6 to 2185.8) |
| Anti-7F OPA Titers, D7 | 25196.4 (21149.5 to 30017.6) | 17828.8 (10270.4 to 30949.7) | 13098.6 (9715.5 to 17659.8) | 19243.4 (15701.4 to 23584.5) |
| Anti-7F OPA Titers, M3 | — | — | — | 9692 (8299.3 to 11318.4) |
| Anti-9V OPA Titers, PRE | — | — | — | 398.2 (253.8 to 624.9) |
| Anti-9V OPA Titers, D7 | 9419.4 (7586 to 11695.9) | 12234.7 (8280.5 to 18077.3) | 7730.3 (5361.8 to 11145.2) | 8322.7 (6605.7 to 10486.1) |
| Anti-9V OPA Titers, M3 | — | — | — | 6456.1 (5458.1 to 7636.6) |
| Anti-14 OPA Titers, PRE | — | — | — | 586.5 (439 to 783.6) |
| Anti-14 OPA Titers, D7 | 8572.3 (7145.4 to 10284.3) | 4192.8 (2218.6 to 7923.7) | 6883.1 (5057.3 to 9368) | 4678.2 (3788 to 5777.5) |
| Anti-14 OPA Titers, M3 | — | — | — | 4891.1 (4178.8 to 5724.8) |
| Anti-18C OPA Titers, PRE | — | — | — | 5.3 (4.2 to 6.6) |
| Anti-18C OPA Titers, D7 | 3378.9 (2652.2 to 4304.8) | 3478.6 (1788.5 to 6765.8) | 1663.2 (970.5 to 2850.2) | 2503.1 (1692.6 to 3701.6) |
| Anti-18C OPA Titers, M3 | — | — | — | 2255.9 (1876.9 to 2711.4) |
| Anti-19F OPA Titers, PRE | — | — | — | 12 (8.3 to 17.5) |
| Anti-19F OPA Titers, D7 | 1346.4 (1068.6 to 1696.5) | 2340.4 (654.8 to 8365.2) | 662.3 (430 to 1020.1) | 700.2 (456.1 to 1074.9) |
| Anti-19F OPA Titers, M3 | — | — | — | 1437.7 (1146.9 to 1802.3) |
| Anti-23F OPA Titers, PRE | — | — | — | 176.4 (83.4 to 373.2) |
| Anti-23F OPA Titers, D7 | 8700.4 (7021.7 to 10780.5) | 11341.1 (5374.6 to 23931) | 7871.9 (4965.3 to 12480.1) | 6813.9 (5249.5 to 8844.6) |
| Anti-23F OPA Titers, M3 | — | — | — | 5586.1 (4666.1 to 6687.5) |
The seropositivity cut-off for the assay was ≥ 0.05 μg/mL. Antibody concentrations against 6A and 19A pneumococcal serotypes were determined as Geometric Mean Antibody Concentrations (GMC) and expressed as micrograms per milliliter (µg/mL).
| μg/mL | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix |
|---|---|---|---|
| Anti-6A antibodies, Y1 | 0.28 (0.24 to 0.32) | 0.44 (0.28 to 0.7) | 0.27 (0.21 to 0.36) |
| Anti-19A antibodies, Y1 | 0.28 (0.25 to 0.32) | 0.21 (0.13 to 0.33) | 0.23 (0.17 to 0.3) |
The seropositivity cut-off for the assay was ≥ 0.05 μg/mL. Antibody concentrations against 6A and 19A pneumococcal serotypes were determined as Geometric Mean Antibody Concentrations (GMC) and expressed as micrograms per milliliter (µg/mL).
| μg/mL | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix |
|---|---|---|---|
| Anti-6A antibodies, Y2 | 0.33 (0.28 to 0.4) | 0.57 (0.3 to 1.11) | 0.4 (0.27 to 0.58) |
| Anti-19A antibodies, Y2 | 0.37 (0.31 to 0.44) | 0.25 (0.14 to 0.44) | 0.35 (0.25 to 0.5) |
Antibody concentrations against 6A and 19A pneumococcal serotypes were determined as Geometric Mean Antibody Concentrations (GMC) and expressed as micro grams per milliliter (µg/mL). The seropositivity cut-off for the assay was ≥ 0.05 μg/mL.
| μg/mL | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix |
|---|---|---|---|
| Anti-6A antibodies, Y4 | 0.92 (0.77 to 1.1) | 0.69 (0.34 to 1.38) | 0.75 (0.55 to 1.03) |
| Anti-19A antibodies, Y4 | 1.3 (1.07 to 1.59) | 1.08 (0.5 to 2.33) | 1.14 (0.77 to 1.68) |
Antibody concentrations against 6A and 19A pneumococcal serotypes were determined as Geometric Mean Antibody Concentrations (GMC) and expressed as micro grams per milliliter (µg/mL). The seropositivity cut-off for the assay was ≥ 0.05 μg/mL.
| μg/mL | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix | Unprimed Group |
|---|---|---|---|---|
| Anti-6A antibodies, PRE | — | — | — | 0.2 (0.15 to 0.27) |
| Anti-6A antibodies, D7 | 2.2 (1.85 to 2.6) | 1.67 (1 to 2.8) | 1.33 (0.96 to 1.83) | 0.44 (0.33 to 0.58) |
| Anti-6A antibodies, M3 | — | — | — | 0.92 (0.73 to 1.16) |
| Anti-19A antibodies, PRE | — | — | — | 0.44 (0.32 to 0.6) |
| Anti-19A antibodies, D7 | 2.79 (2.33 to 3.35) | 2.44 (1.2 to 4.96) | 1.72 (1.14 to 2.61) | 1.1 (0.84 to 1.45) |
| Anti-19A antibodies, M3 | — | — | — | 2.39 (1.9 to 3.01) |
Opsonophagocytic activity were assessed for pneumococcal serotypes 6A and 19A (OPA-6A and OPA-19A). The seropositivity cut-off for the assay was ≥ 8. Opsonophagocytic activity was expressed as Geometric Mean Antibody Titers (GMT).
| Titers | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix |
|---|---|---|---|
| Anti-6A OPA Titers, Y1 | 59 (45.9 to 76) | 610.2 (317.7 to 1171.9) | 46.6 (28.3 to 76.8) |
| Anti-19A OPA Titers, Y1 | 6 (5.2 to 6.8) | 5.9 (3.7 to 9.5) | 5.5 (4.5 to 6.8) |
Opsonophagocytic activity were assessed for pneumococcal serotypes 6A and 19A (OPA-6A and OPA-19A). The seropositivity cut-off for the assay was ≥ 8. Opsonophagocytic activity was expressed as Geometric Mean Antibody Titers (GMT).
| Titers | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix |
|---|---|---|---|
| Anti-6A OPA Titers, Y2 | 121.8 (95.2 to 156) | 356.5 (134.6 to 944.6) | 133.7 (81.8 to 218.7) |
| Anti-19A OPA Titers, Y2 | 12.8 (10.4 to 15.7) | 10.9 (5.2 to 22.8) | 11.1 (7.6 to 16.2) |
Opsonophagocytic activity were assessed for pneumococcal serotypes 6A and 19A (OPA-6A and OPA-19A). The seropositivity cut-off for the assay was ≥ 8. Opsonophagocytic activity was expressed as Geometric Mean Antibody Titers (GMT).
| Titers | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix |
|---|---|---|---|
| Anti-6A OPA Titers, Y4 | 213.5 (165.4 to 275.7) | 227.8 (72.1 to 720) | 153.5 (90.5 to 260.2) |
| Anti-19A OPA Titers, Y4 | 31.2 (23.6 to 41.3) | 14.3 (5.6 to 36.8) | 21.8 (13.3 to 35.7) |
Opsonophagocytic activity were assessed for pneumococcal serotypes 6A and 19A (OPA-6A and OPA-19A). The seropositivity cut-off for the assay was ≥ 8. Opsonophagocytic activity was expressed as Geometric Mean Antibody Titers (GMT).
| Titers | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix | Unprimed Group |
|---|---|---|---|---|
| Anti-6A OPA Titers, PRE | — | — | — | 102.6 (61.5 to 171.2) |
| Anti-6A OPA Titers, D7 | 1217.7 (957.8 to 1548.2) | 1490.2 (681.6 to 3257.8) | 467.7 (293.8 to 744.5) | 826.5 (593.9 to 1150.2) |
| Anti-6A OPA Titers, M3 | — | — | — | 943.4 (691.3 to 1287.4) |
| Anti-19A OPA Titers, PRE | — | — | — | 9.9 (7 to 13.8) |
| Anti-19A OPA Titers, D7 | 467 (335 to 651.1) | 437.6 (81.3 to 2356.3) | 106.1 (54.1 to 208.3) | 431.2 (269.4 to 689.9) |
| Anti-19A OPA Titers, M3 | — | — | — | 376.4 (256.3 to 552.6) |
Anti-protein D (Anti-PD) antibody concentrations by Enzyme-Linked Immunosorbent Assay (ELISA) were calculated, expressed as geometric mean concentrations (GMCs) in ELISA unit per milli-liter (EL.U/mL) and tabulated. The seropositivity cut-off for the assay was ≥ 100 EL.U/mL.
| EL.U/mL | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix |
|---|---|---|---|
| Antibody Concentrations to Protein D (Anti-PD) - Follow-up Period: Persistence Analysis in Year 1 (111345 Sub-study) | 822.1 (731.5 to 923.9) | 93.9 (66.6 to 132.3) | 193.6 (155.9 to 240.4) |
Anti-protein D (Anti-PD) antibody concentrations by Enzyme-Linked Immunosorbent Assay (ELISA) were calculated, expressed as geometric mean concentrations (GMCs) in ELISA unit per milli-liter (EL.U/mL) and tabulated. The seropositivity cut-off for the assay was ≥ 100 EL.U/mL.
| EL.U/mL | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix |
|---|---|---|---|
| Antibody Concentrations to Protein D (Anti-PD) - Follow-up Period: Persistence Analysis in Year 2 (111346 Sub-study) | 573.2 (509.6 to 644.8) | 116.7 (80.9 to 168.3) | 157.5 (128.7 to 192.8) |
Anti-protein D (Anti-PD) antibody concentrations by Enzyme-Linked Immunosorbent Assay (ELISA) were calculated, expressed as geometric mean concentrations (GMCs) in ELISA unit per milli-liter (EL.U/mL) and tabulated. The seropositivity cut-off for the assay was ≥ 100 EL.U/mL.
| EL.U/mL | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix |
|---|---|---|---|
| Antibody Concentrations to Protein D (Anti-PD) [Follow-up Period: Persistence Analysis in Year 4 (111347 Sub-study)] | 372.4 (329.6 to 420.9) | 144.9 (86.3 to 243.2) | 161.4 (128.4 to 203) |
Anti-protein D (Anti-PD) antibody concentrations by Enzyme-Linked Immunosorbent Assay (ELISA) were calculated, expressed as geometric mean concentrations (GMCs) in ELISA unit per milli-liter (EL.U/mL) and tabulated. The seropositivity cut-off for the assay was ≥ 100 EL.U/mL.
| EL.U/mL | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix | Unprimed Group |
|---|---|---|---|---|
| Anti-PD antibodies, PRE | — | — | — | 106 (91.1 to 123.4) |
| Anti-PD antibodies, D7 | 2106 (1806.7 to 2454.9) | 718.2 (442.5 to 1165.7) | 680.7 (522.9 to 886.2) | 382.9 (320.7 to 457.2) |
| Anti-PD antibodies, M3 | — | — | — | 708.6 (604.6 to 830.4) |
Solicited local symptoms assessed were pain, redness and swelling. Any occurrence of symptom regardless of intensity grade. Any Redness or any Swelling symptom = any symptom greater than (\>) 0 millimeter (mm). Grade 3 pain = maximum intensity of local injection defined as subject crying when limb was moved/spontaneously painful. Grade 3 redness/swelling= maximum intensity of local injection \>30 mm. Follow-up period was of 4 days (Days 0-3) after Synflorix vaccination in Year 4 Persistence and Immunological Memory 111347 Study, thus one period of 4 days for primed subjects and 2 periods of 4 days for unprimed subjects.
| Participants | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix | Unprimed Group |
|---|---|---|---|---|
| Pain, Any | 157 | 9 | 34 | 54 |
| Redness, Any | 90 | 5 | 14 | 21 |
| Swelling, Any | 67 | 4 | 15 | 20 |
| Pain, Grade 3 | 7 | 1 | 5 | 3 |
| Redness, Grade 3 (> 30 mm) | 7 | 0 | 0 | 1 |
| Swelling, Grade 3 (> 30 mm) | 5 | 0 | 1 | 2 |
Solicited general symptoms assessed were drowsiness, irritability, loss of appetite and fever (any fever defined as temperature by axillary measurement of 37.5°C and above). Grade 3 drowsiness was defined as drowsiness that prevented normal activity; Grade 3 irritability was defined as crying that could not be comforted/prevented normal activity. Grade 3 loss of appetite was defined as subject not eating at all. Grade 3 fever was defined as axillary temperature \>39.5°C. Related AE was defined as any AE assessed by investigators to be causally related to administration of the study vaccine. Follow-up period was of 4 days (Days 0-3) after Synflorix vaccination in Year 4 Persistence and Immunological Memory 111347 Study, thus one period of 4 days for primed subjects and 2 periods of 4 days for unprimed subjects.
| Participants | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix | Unprimed Group |
|---|---|---|---|---|
| Drowsiness, Any | 49 | 2 | 12 | 12 |
| Drowsiness, Grade 3 | 1 | 0 | 0 | 0 |
| Drowsiness, Related | 48 | 2 | 11 | 11 |
| Irritability, Any | 35 | 4 | 6 | 8 |
| Irritability, Related | 35 | 4 | 6 | 8 |
| Irritability, Grade 3 | 0 | 0 | 0 | 0 |
| Loss of appetite, Any | 30 | 3 | 6 | 13 |
| Loss of appetite, Grade 3 | 1 | 0 | 1 | 0 |
| Loss of appetite, Related | 30 | 3 | 5 | 11 |
| Fever, Any | 13 | 0 | 2 | 5 |
| Fever, >39,5°C | 0 | 0 | 0 | 0 |
| Fever, Related | 13 | 0 | 1 | 5 |
An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. "Any" was defined an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination. Follow-up period was of 31 days (Days 0-30) after Synflorix vaccination in Year 4 Persistence and Immunological Memory 111347 Study, thus one period of 31 days for primed subjects and 2 periods of 31 days for unprimed subjects.
| Participants | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix | Unprimed Group |
|---|---|---|---|---|
| Number of Subjects With Unsolicited Adverse Events (AEs) | 25 | 0 | 3 | 6 |
An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or may evolve into one of the outcomes listed above. "Any" was defined an incidence of a SAE regardless of intensity/severity.
| Participants | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix |
|---|---|---|---|
| Number of Subjects With Serious Adverse Events (SAEs) Related to Study Procedures [Follow-up Period: Year 1 (111345 Sub-study)] | 1 | 0 | 0 |
An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or may evolve into one of the outcomes listed above. "Any" is defined an incidence of a SAE regardless of intensity/severity.
| Participants | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix |
|---|---|---|---|
| Number of Subjects With Serious Adverse Events (SAEs) Related to Study Procedures [(Follow-up Period: Year 2 (111346 Sub-study) Until Year 4 (111347 Sub-study)] | 0 | 0 | 0 |
An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or may evolve into one of the outcomes listed above. "Any" is defined an incidence of a SAE regardless of intensity/severity.
| Participants | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix | Unprimed Group |
|---|---|---|---|---|
| Number of Subjects With Serious Adverse Events (SAEs) [Follow-up Period: Vaccination Period in Year 4 (111347 Sub-study)] | 0 | 0 | 0 | 0 |
A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Pneumococcal serotypes assessed were 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. The seropositivity cut-off for the assay was 8.
| Participants | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix |
|---|---|---|---|
| Anti-1 OPA, Y1 | 188 | 2 | 26 |
| Anti-4 OPA, Y1 | 201 | 21 | 65 |
| Anti-5 OPA, Y1 | 241 | 2 | 46 |
| Anti-6B OPA, Y1 | 164 | 23 | 44 |
| Anti-7F OPA, Y1 | 343 | 20 | 85 |
| Anti-9V OPA, Y1 | 351 | 26 | 90 |
| Anti-14 OPA, Y1 | 336 | 25 | 89 |
| Anti-18C OPA, Y1 | 173 | 10 | 25 |
| Anti-19F OPA, Y1 | 306 | 19 | 83 |
| Anti-23F OPA, Y1 | 301 | 26 | 82 |
A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Pneumococcal serotypes assessed were 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. The seropositivity cut-off for the assay was 8.
| Participants | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix |
|---|---|---|---|
| Anti-1 OPA, Y2 | 92 | 0 | 15 |
| Anti-4 OPA, Y2 | 146 | 12 | 48 |
| Anti-5 OPA, Y2 | 169 | 2 | 31 |
| Anti-6B OPA, Y2 | 241 | 24 | 67 |
| Anti-7F OPA Titers, Y2 | 350 | 26 | 90 |
| Anti-9V OPA, Y2 | 347 | 27 | 87 |
| Anti-14 OPA, Y2 | 333 | 24 | 85 |
| Anti-18C OPA, Y2 | 165 | 11 | 29 |
| Anti-19F OPA, Y2 | 279 | 21 | 78 |
| Anti-23F OPA, Y2 | 285 | 25 | 72 |
A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Pneumococcal serotypes assessed were 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. The seropositivity cut-off for the assay was 8.
| Participants | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix |
|---|---|---|---|
| Anti-1 OPA, Y4 | 55 | 1 | 17 |
| Anti-4 OPA, Y4 | 107 | 8 | 33 |
| Anti-5 OPA, Y4 | 80 | 2 | 11 |
| Anti-6B OPA, Y4 | 223 | 15 | 62 |
| Anti-7F OPA, Y4 | 248 | 15 | 71 |
| Anti-9V OPA, Y4 | 242 | 14 | 68 |
| Anti-14 OPA, Y4 | 247 | 14 | 70 |
| Anti-18C OPA, Y4 | 121 | 8 | 27 |
| Anti-19F OPA, Y4 | 211 | 14 | 62 |
| Anti-23F OPA, Y4 | 209 | 15 | 55 |
A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Pneumococcal serotypes assessed were 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. Analysis was performed with Unprimed group included. The seropositivity cut-off for the assay was 8.
| Participants | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix | Unprimed Group |
|---|---|---|---|---|
| Anti-1 OPA, PRE | — | — | — | 8 |
| Anti-1 OPA, D7 | 193 | 13 | 48 | 90 |
| Anti-1 OPA, M3 | — | — | — | 87 |
| Anti-4 OPA, PRE | — | — | — | 17 |
| Anti-4 OPA, D7 | 194 | 13 | 50 | 93 |
| Anti-4 OPA, M3 | — | — | — | 94 |
| Anti-5 OPA, PRE | — | — | — | 8 |
| Anti-5 OPA, D7 | 186 | 13 | 47 | 87 |
| Anti-5 OPA, M3 | — | — | — | 89 |
| Anti-6B OPA, PRE | — | — | — | 35 |
| Anti-6B OPA, D7 | 196 | 13 | 48 | 84 |
| Anti-6B OPA, M3 | — | — | — | 94 |
| Anti-7F OPA, PRE | — | — | — | 67 |
| Anti-7F OPA, D7 | 199 | 13 | 50 | 93 |
| Anti-7F OPA, M3 | — | — | — | 93 |
| Anti-9V OPA, PRE | — | — | — | 75 |
| Anti-9V OPA, D7 | 201 | 13 | 51 | 93 |
| Anti-9V OPA, M3 | — | — | — | 94 |
| Anti-14 OPA, PRE | — | — | — | 81 |
| Anti-14 OPA, D7 | 197 | 13 | 51 | 94 |
| Anti-14 OPA, M3 | — | — | — | 95 |
| Anti-18C OPA, PRE | — | — | — | 7 |
| Anti-18C OPA, D7 | 190 | 13 | 48 | 88 |
| Anti-18C OPA, M3 | — | — | — | 92 |
| Anti-19F OPA, PRE | — | — | — | 30 |
| Anti-19F OPA, D7 | 194 | 13 | 50 | 91 |
| Anti-19F OPA, M3 | — | — | — | 93 |
| Anti-23F OPA, PRE | — | — | — | 47 |
| Anti-23F OPA, D7 | 197 | 13 | 49 | 95 |
| Anti-23F OPA, M3 | — | — | — | 95 |
A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Pneumococcal serotypes assessed were 6A and 19A. The results for the immune responses were measured by 22F-inhibition ELISA. The seropositivity cut-off for the assay was 0.05 μg/mL.
| Participants | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix |
|---|---|---|---|
| Anti-6A antibodies, Y1 | 376 | 31 | 97 |
| Anti-19A antibodies, Y1 | 366 | 29 | 93 |
A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Pneumococcal serotypes assessed were 6A and 19A. The immune responses were measured by 22F-inhibation ELISA. The seropositivity cut-off for the assay was 0.05 μg/mL.
| Participants | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix |
|---|---|---|---|
| Anti-6A antibodies, Y2 | 330 | 30 | 86 |
| Anti-19A antibodies, Y2 | 319 | 25 | 83 |
A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Pneumococcal serotypes assessed were 6A and 19A. The immune responses were measured by 22F-inhibition ELISA. The seropositivity cut-off for the assay was 0.05 μg/mL.
| Participants | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix |
|---|---|---|---|
| Anti-6A antibodies, Y4 | 256 | 18 | 72 |
| Anti-19A antibodies, Y4 | 260 | 18 | 74 |
A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Pneumococcal serotypes assessed were 6A and 19A. The immune responses were measured by 22F-inhibition ELISA. The seropositivity cut-off for the assay was 0.05 μg/mL.
| Participants | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix | Unprimed Group |
|---|---|---|---|---|
| Anti-6A antibodies, PRE | — | — | — | 76 |
| Anti-6A antibodies, D7 | 208 | 14 | 54 | 92 |
| Anti-6A antibodies, M3 | — | — | — | 97 |
| Anti-19A antibodies, PRE | — | — | — | 88 |
| Anti-19A antibodies, D7 | 208 | 14 | 54 | 97 |
| Anti-19A antibodies, M3 | — | — | — | 98 |
A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Pneumococcal serotypes assessed were 6A and 19A. The immune responses were mesured by Opsonophagocytic activity (OPA). The seropositivity cut-off for the assay was 8.
| Participants | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix |
|---|---|---|---|
| Anti-6A OPA, Y1 | 196 | 24 | 45 |
| Anti-19A OPA, Y1 | 45 | 3 | 10 |
A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Pneumococcal serotypes assessed were 6A and 19A. The immune responses were measured by Opsonophagocytic activity (OPA). The seropositivity cut-off for the assay was 8.
| Participants | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix |
|---|---|---|---|
| Anti-6A OPA, Y2 | 235 | 21 | 62 |
| Anti-19A OPA, Y2 | 115 | 8 | 29 |
A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Pneumococcal serotypes assessed were 6A and 19A. The immune responses were measured by Opsonophagocytic Activity (OPA). The seropositivity cut-off for the assay was 8.
| Participants | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix |
|---|---|---|---|
| Anti-6A OPA Titers, Y4 | 194 | 12 | 51 |
| Anti-19A OPA Titers, Y4 | 135 | 7 | 34 |
A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Pneumococcal serotypes assessed were 6A and 19A. The immune responses were measured by Opsonophagocytic Activity (OPA). The seropositivity cut-off for the assay was 8.
| Participants | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix | Unprimed Group |
|---|---|---|---|---|
| Anti-6A OPA, PRE | — | — | — | 57 |
| Anti-6A OPA, D7 | 185 | 12 | 46 | 88 |
| Anti-6A OPA, M3 | — | — | — | 87 |
| Anti-19A OPA, PRE | — | — | — | 25 |
| Anti-19A OPA, D7 | 173 | 11 | 36 | 81 |
| Anti-19A OPA, M3 | — | — | — | 87 |
A seropositive subject was a subject whose anti-PD antibody concentration was greater than or equal to (≥) the cut-off value. The seropositivity cut-off for the assay was 100 EL.U/ML.
| Participants | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix |
|---|---|---|---|
| Number of Seropositive Subjects for Anti-protein D (Anti-PD) [Follow-up Period: Persistence Analysis in Year 1 (111345 Sub-study)] | 373 | 11 | 71 |
A seropositive subject was a subject whose anti-PD antibody concentration was greater than or equal to (≥) the cut-off value. The seropositivity cut-off for the assay was 100 EL.U/ML.
| Participants | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix |
|---|---|---|---|
| Number of Seropositive Subjects for Anti Protein D (Anti-PD) [Follow-up Period: Persistence Analysis in Year 2 (111345 Sub-study)] | 340 | 15 | 65 |
A seropositive subject was a subject whose anti-PD antibody concentration was greater than or equal to (≥) the cut-off value. The seropositivity cut-off for the assay was 100 EL.U/ML.
| Participants | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix |
|---|---|---|---|
| Number of Seropositive Subjects for Anti-protein D (Anti-PD) [Follow-up Period: Persistence Analysis in Year 4 (111347 Sub-study)] | 241 | 12 | 54 |
A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. The seropositivity cut-off for the assay was 100 EL.U/ML.
| Participants | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix | Unprimed Group |
|---|---|---|---|---|
| Anti-PD antibodies, PRE | — | — | — | 54 |
| Anti-PD antibodies, D7 | 207 | 14 | 54 | 92 |
| Anti-PD antibodies, M3 | — | — | — | 98 |
A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Analysis was performed using the 22F-inhibition Enzyme-linked immunosorbent assay (ELISA), using 0.05 microgram per milliliter (µg/mL) as seropositivity cut off.
| Participants | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix | Unprimed Group |
|---|---|---|---|---|
| Anti-1 antibodies, PRE | — | — | — | 69 |
| Anti-1 antibodies, D7 | 207 | 14 | 54 | 97 |
| Anti-1 antibodies, M3 | — | — | — | 98 |
| Anti-4 antibodies, PRE | — | — | — | 29 |
| Anti-4 antibodies, D7 | 208 | 14 | 54 | 98 |
| Anti-4 antibodies, M3 | — | — | — | 98 |
| Anti-5 antibodies, PRE | — | — | — | 72 |
| Anti-5 antibodies, D7 | 207 | 14 | 54 | 98 |
| Anti-5 antibodies, M3 | — | — | — | 98 |
| Anti-6B antibodies, PRE | — | — | — | 77 |
| Anti-6B antibodies, D7 | 207 | 14 | 54 | 94 |
| Anti-6B antibodies, M3 | — | — | — | 98 |
| Anti-7F antibodies, PRE | — | — | — | 64 |
| Anti-7F antibodies, D7 | 208 | 14 | 54 | 98 |
| Anti-7F antibodies, M3 | — | — | — | 98 |
| Anti-9V antibodies, PRE | — | — | — | 67 |
| Anti-9V antibodies, D7 | 208 | 14 | 54 | 94 |
| Anti-9V antibodies, M3 | — | — | — | 98 |
| Anti-14 antibodies, PRE | — | — | — | 90 |
| Anti-14 antibodies, D7 | 208 | 14 | 54 | 97 |
| Anti-14 antibodies, M3 | — | — | — | 98 |
| Anti-18C antibodies, PRE | — | — | — | 52 |
| Anti-18C antibodies, D7 | 207 | 14 | 54 | 97 |
| Anti-18C antibodies, M3 | — | — | — | 98 |
| Anti-19F antibodies, PRE | — | — | — | 75 |
| Anti-19F antibodies, D7 | 208 | 14 | 54 | 97 |
| Anti-19F antibodies, M3 | — | — | — | 98 |
| Anti-23F antibodies, PRE | — | — | — | 54 |
| Anti-23F antibodies, D7 | 208 | 14 | 54 | 90 |
| Anti-23F antibodies, M3 | — | — | — | 98 |
Collected over Solicited and Unsolicited AEs were collected within 4 days and 31 days post-Synflorix vaccination, respectively, for subjects participating to Year 4 follow-up period. SAEs related to study procedure were collected at Year 1 in sub-study 111345 and from Year 2 up to Year 4 follow-up period in sub-studies 111346-111347 for primed subjects. Any SAEs were collected during the vaccination period in the111347 study (i.e. from Month 48-49 for primed subjects and from Month 0-3 for unprimed subjects).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Synflorix + Infanrix + Havrix and/or Varilrix Group | 0/391 (0%) | 1/391 (0.3%) | 188/264 (71.2%) |
| Prevenar + Infanrix + Havrix and/or Varilrix Group | 0/31 (0%) | 0/31 (0%) | 12/20 (60%) |
| Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix | 0/102 (0%) | 0/102 (0%) | 39/65 (60%) |
| Unprimed Group | 0/100 (0%) | 0/100 (0%) | 65/100 (65%) |
| Event | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix | Unprimed Group |
|---|---|---|---|---|
| BroncopneumoniaInfections and infestations | 1/391 | 0/31 | 0/102 | 0/100 |
| Event | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix | Unprimed Group |
|---|---|---|---|---|
| PainGeneral disorders | 157/264 | 9/20 | 34/64 | 54/100 |
| RednessGeneral disorders | 90/264 | 5/20 | 14/64 | 21/100 |
| SwellingGeneral disorders | 67/264 | 4/20 | 15/64 | 20/100 |
| IrritabilityGeneral disorders | 35/263 | 4/20 | 6/64 | 8/100 |
| DrowsinessGeneral disorders | 49/263 | 2/20 | 12/64 | 12/100 |
| Loss of appetiteGeneral disorders | 30/263 | 3/20 | 6/64 | 13/100 |
| Fever (Axillary temperature ≥ 37.5°C)General disorders | 13/263 | 0/20 | 2/64 | 5/100 |
The demographic characteristics are presented separately for each Follow-up Period (Year 1, 2 and 4).
| Age, Continuous(Months) | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix | Unprimed Group | Total |
|---|---|---|---|---|---|
| Mean | 29.1 ± 0.88 | 29.0 ± 0.75 | 29.1 ± 0.81 | — | 29.1 ± 0.86 |
| Age, Continuous(Months) | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix | Unprimed Group | Total |
|---|---|---|---|---|---|
| Mean | 41.1 ± 1.04 | 41.1 ± 1.09 | 41.2 ± 1.04 | — | 41.1 ± 1.04 |
| Age, Continuous(Months) | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix | Unprimed Group | Total |
|---|---|---|---|---|---|
| Mean | 67.4 ± 0.84 | 67.1 ± 0.97 | 67.3 ± 0.89 | 65.4 ± 1.31 | 66.9 ± 1.28 |
| Sex: Female, Male(Participants) | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix | Unprimed Group | Total |
|---|---|---|---|---|---|
| Female | 203 | 14 | 52 | — | 269 |
| Male | 188 | 17 | 50 | — | 255 |
| Sex: Female, Male(Participants) | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix | Unprimed Group | Total |
|---|---|---|---|---|---|
| Female | 192 | 14 | 50 | — | 256 |
| Male | 178 | 17 | 46 | — | 241 |
| Sex: Female, Male(Participants) | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix | Unprimed Group | Total |
|---|---|---|---|---|---|
| Female | 139 | 10 | 35 | 53 | 237 |
| Male | 125 | 10 | 30 | 47 | 212 |
| Race/Ethnicity, Customized(Participants) | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix | Unprimed Group | Total |
|---|---|---|---|---|---|
| White - caucasia/ european heritage | 386 | 31 | 102 | 0 | 519 |
| White arabic/ north african heritage | 4 | 0 | 4 | 0 | 8 |
| Other, not specified | 1 | 0 | 0 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Synflorix + Infanrix + Havrix and/or Varilrix Group | Prevenar + Infanrix + Havrix and/or Varilrix Group | Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix | Unprimed Group | Total |
|---|---|---|---|---|---|
| White - Caucasian / European heritage | 365 | 31 | 96 | 0 | 492 |
| White - Arabic / North African heritage | 4 | 0 | 0 | 0 | 4 |
| Other, not specified | 1 | 0 | 0 | 0 | 1 |
1 further baseline measures are reported on the registry.
Plan to share: Yes — IPD is available via the Clinical Study Data Request site (click on the link provided below)
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · www.clinicalstudydatarequest.com
Ran from Mar 2008 to primary completion in Jun 2008, 2 months.
Results were first posted in Mar 2020, 11 years 9 months after primary completion. A results delay was requested in Jul 2012.
Of 28 industry-sponsored phase 3 interventional studies under Streptococcal Infections, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 13. This study's 2 months is below that.
Counting every sponsor, half of 29 studies reached it within 10 months; a quarter within 8 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: PHiD-CV vaccine · Heptavalent Pneumococcal Conjugate Vaccine · Diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine · Chickenpox Vaccine